SEC Comment Letter for SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478) (SLS) — Oct 14, 2016
SELLAS Life Sciences Group, Inc. (SLS) (CIK 0001390478)
Date: Oct. 14, 2016 · CIK: 0001390478 · Accession: 0000000000-16-097048
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-213908
Letter
Mail Stop 4546 October 13, 2016 Dr. Mark W. Schwartz President & Chief Executive Officer Galena Biopharma, Inc. 2000 Crow Canyon Place, Suite 380 San Ramon, California 94583
Re: Galena Biopharma, Inc. Registration Statement on Form S-3 Filed September 30, 2016 File No. 333-213908
Dear Dr. Schwartz :
We have limited our review of your registration statement to those issues w e have addressed in our comment .
Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our com ment appl ies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments.
Incorporation of Certain Documents by Reference, page 29
1. Please update this section to incorporate by reference your Current Report on Form 8 -K filed on October 6 , 2016 . For reference, please see Compliance and Disclosure Interpretations, Securities Act Forms , Question 123.05 .
We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration . Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement.
Dr. Mark W. Schwartz Galena Biopharma, Inc. October 13, 2016 Page 2
Please contact Dorrie Yale at 202 -551-8776 or Mary Beth Breslin at 202 -551-3625 with any questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4546 October 13, 2016 Dr. Mark W. Schwartz President & Chief Executive Officer Galena Biopharma, Inc. 2000 Crow Canyon Place, Suite 380 San Ramon, California 94583 Re: Galena Biopharma, Inc. Registration Statement on Form S-3 Filed September 30, 2016 File No. 333-213908 Dear Dr. Schwartz : We have limited our review of your registration statement to those issues w e have addressed in our comment . Please respond to this letter by amending your registration statement and providing the requested information . If you do not believe our com ment appl ies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to the comment, we may have additional comments. Incorporation of Certain Documents by Reference, page 29 1. Please update this section to incorporate by reference your Current Report on Form 8 -K filed on October 6 , 2016 . For reference, please see Compliance and Disclosure Interpretations, Securities Act Forms , Question 123.05 . We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration . Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Dr. Mark W. Schwartz Galena Biopharma, Inc. October 13, 2016 Page 2 Please contact Dorrie Yale at 202 -551-8776 or Mary Beth Breslin at 202 -551-3625 with any questions. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Insurance and Healthcare cc: Thomas J. Knap p